132 related articles for article (PubMed ID: 11747276)
41. [Micrometastases in pediatric oncology].
Bernard F; Aerts I; Margueritte G; Astruc J
Bull Cancer; 2001 Jun; 88(6):577-80. PubMed ID: 11459704
[TBL] [Abstract][Full Text] [Related]
42. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer.
Cooper BW; Moss TJ; Ross AA; Ybanez J; Lazarus HM
J Clin Oncol; 1998 Nov; 16(11):3509-17. PubMed ID: 9817268
[TBL] [Abstract][Full Text] [Related]
43. Occult metastases in patients with breast cancer.
Hawes D; Neville AM; Cote RJ
Ann Surg Oncol; 2001 Oct; 8(9 Suppl):60S-63S. PubMed ID: 11599903
[TBL] [Abstract][Full Text] [Related]
44. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer.
Köllermann J; Heseding B; Helpap B; Köllermann MW; Pantel K
Int J Cancer; 1999 Apr; 84(2):145-9. PubMed ID: 10096246
[TBL] [Abstract][Full Text] [Related]
45. Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer.
Pantel K; Aignherr C; Köllermann J; Caprano J; Riethmüller G; Köllermann MW
Eur J Cancer; 1995 Sep; 31A(10):1627-32. PubMed ID: 7488413
[TBL] [Abstract][Full Text] [Related]
46. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.
Slade MJ; Singh A; Smith BM; Tripuraneni G; Hall E; Peckitt C; Fox S; Graham H; Lüchtenborg M; Sinnett HD; Cross NC; Coombes RC
Int J Cancer; 2005 Mar; 114(1):94-100. PubMed ID: 15523696
[TBL] [Abstract][Full Text] [Related]
47. Bone marrow micrometastasis in breast cancer.
Ozbas S; Dafydd H; Purushotham AD
Br J Surg; 2003 Mar; 90(3):290-301. PubMed ID: 12594663
[TBL] [Abstract][Full Text] [Related]
48. Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining.
Thorban S; Roder JD; Pantel K; Siewert JR
Eur J Cancer; 1996 Feb; 32A(2):363-5. PubMed ID: 8664055
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues.
Vincent-Salomon A; Bidard FC; Pierga JY
J Clin Pathol; 2008 May; 61(5):570-6. PubMed ID: 18037661
[TBL] [Abstract][Full Text] [Related]
50. In vitro detection of occult bone marrow metastases in patients with colorectal cancer hepatic metastases.
Cohen AM; Garin-Chesa P; Hanson M; Weyhrauch K; Kemeny N; Fong Y; Paty P; Welt S; Old L
Dis Colon Rectum; 1998 Sep; 41(9):1112-5. PubMed ID: 9749494
[TBL] [Abstract][Full Text] [Related]
51. Minimal residual disease in bone marrow and peripheral blood of patients with metastatic breast cancer.
Bischoff J; Rosenberg R; Dahm M; Janni W; Gutschow K
Recent Results Cancer Res; 2003; 162():135-40. PubMed ID: 12790327
[TBL] [Abstract][Full Text] [Related]
52. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.
Heiss MM; Allgayer H; Gruetzner KU; Funke I; Babic R; Jauch KW; Schildberg FW
Nat Med; 1995 Oct; 1(10):1035-9. PubMed ID: 7489359
[TBL] [Abstract][Full Text] [Related]
53. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer.
Buergy D; Fuchs T; Kambakamba P; Mudduluru G; Maurer G; Post S; Tang Y; Nakada MT; Yan L; Allgayer H
Cancer; 2009 Oct; 115(20):4667-78. PubMed ID: 19569245
[TBL] [Abstract][Full Text] [Related]
54. Analysis of sensitivity and specificity of cytokeratin 19 reverse transcriptase/polymerase chain reaction for detection of occult breast cancer in bone marrow and leukapheresis products.
Zhong XY; Kaul S; Diel I; Eichler A; Bastert G
J Cancer Res Clin Oncol; 1999; 125(5):286-91. PubMed ID: 10359133
[TBL] [Abstract][Full Text] [Related]
55. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.
Thorban S; Roder JD; Nekarda H; Funk A; Siewert JR; Pantel K
J Natl Cancer Inst; 1996 Sep; 88(17):1222-7. PubMed ID: 8780632
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA.
Ikeda N; Miyoshi Y; Motomura K; Inaji H; Koyama H; Noguchi S
Jpn J Cancer Res; 2000 Sep; 91(9):918-24. PubMed ID: 11011120
[TBL] [Abstract][Full Text] [Related]
57. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
[TBL] [Abstract][Full Text] [Related]
58. [Can detection of cancer cells in bone marrow and peripheral blood be used in diagnosis and patient monitoring?].
Werther K; Brünner NA; Nielsen HJ
Ugeskr Laeger; 1998 Oct; 160(41):5923-6. PubMed ID: 9786030
[TBL] [Abstract][Full Text] [Related]
59. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance.
Choesmel V; Pierga JY; Nos C; Vincent-Salomon A; Sigal-Zafrani B; Thiery JP; Blin N
Breast Cancer Res; 2004; 6(5):R556-70. PubMed ID: 15318937
[TBL] [Abstract][Full Text] [Related]
60. [Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma].
Thorban S; Roder JD; Pantel K; Siewert JR
Zentralbl Chir; 1996; 121(6):487-9; discussion 490-2. PubMed ID: 8767337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
